Rituximab Therapy in Idiopathic Membranous Nephropathy | Zendy

Fernando C. Fervenza | Zendy; Roshini S. Abraham | Zendy; Stephen B. Erickson | Zendy; María V. Irazabal | Zendy; Alfonso Eirin | Zendy; Ulrich Specks | Zendy; Patrick H. Nachman | Zendy; Eric J. Bergstralh | Zendy; Nelson Leung | Zendy; Fernando G. Cosio | Zendy; Marie C. Hogan | Zendy; John Dillon | Zendy; LaTonya J. Hickson | Zendy; Xujian Li | Zendy; Daniel Cattran | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Rituximab Therapy in Idiopathic Membranous Nephropathy

Author(s) -

Fernando C. Fervenza,

Roshini S. Abraham,

Stephen B. Erickson,

María V. Irazabal,

Alfonso Eirin,

Ulrich Specks,

Patrick H. Nachman,

Eric J. Bergstralh,

Nelson Leung,

Fernando G. Cosio,

Marie C. Hogan,

John Dillon,

LaTonya J. Hickson,

Xujian Li,

Daniel Cattran

Publication year - 2010

Publication title -

clinical journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.755

H-Index - 151

eISSN - 1555-905X

pISSN - 1555-9041

DOI - 10.2215/cjn.05080610

Subject(s) - medicine , proteinuria , rituximab , membranous nephropathy , gastroenterology , creatinine , regimen , lymphocyte , renal function , nephropathy , urology , immunology , endocrinology , kidney , lymphoma , diabetes mellitus

It was postulated that in patients with membranous nephropathy (MN), four weekly doses of Rituximab (RTX) would result in more effective B cell depletion, a higher remission rate, and maintaining the same safety profile compared with patients treated with RTX dosed at 1 g every 2 weeks. This hypothesis was supported by previous pharmacokinetic (PK) analysis showing that RTX levels in the two-dose regimen were 50% lower compared with nonproteinuric patients, which could potentially result in undertreatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research